Systematic improvement of lentivirus transduction protocols by antibody fragments fused to VSV-G as envelope glycoprotein

Biomaterials

Volumn 35, Issue 13, 2014, Pages 4204-4212

  Höfig, Ines ^a   Barth, Stefan ^b   Salomon, M ^c   Jagusch, Verena ^c   Atkinson, Mike J ^a   Anastasov, Natasa ^a   Thirion, Christian ^c  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^c SIRION BIOTECH GMBH   (Germany)

Author keywords

Gene delivery; Gene transfer; Lentivirus; Poloxamer; ScFv; VSV G retargeting

Indexed keywords

GENE DELIVERY; LENTIVIRUS; POLOXAMER; SCFV; VSV-G RETARGETING;

BACTERIOPHAGES; CELL CULTURE; CELLS; EFFICIENCY; GENE TRANSFER; GLYCOPROTEINS; OPTIMIZATION;

ANTIBODIES;

CD30 ANTIGEN; LENTIVIRUS VECTOR; POLOXAMER; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS GLYCOPROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; GLYCOPROTEIN; IMMUNOGLOBULIN FRAGMENT; MEMBRANE PROTEIN;

ARTICLE; CELL SPECIFICITY; GENE TARGETING; HUMAN; HUMAN CELL; LENTIVIRUS INFECTION; LYMPHOMA CELL; MIXED CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS ENVELOPE; CELL LINE; CHEMISTRY; GENE TRANSFER; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; LENTIVIRINAE; PROCEDURES;

LENTIVIRUS; VESICULAR STOMATITIS VIRUS;

CELL LINE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; LENTIVIRUS; MEMBRANE GLYCOPROTEINS; TRANSDUCTION, GENETIC; VIRAL ENVELOPE PROTEINS;

EID: 84896739248     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.01.051     Document Type: Article

References (43)

1. Bukrinsky M.I., Haggerty S., Dempsey M.P., Sharova N., Adzhubel A., Spitz L., et al. Anuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 1993, 365:666-669.
2. Gaspar H.B., Cooray S., Gilmour K.C., Parsley K.L., Zhang F., Adams S., et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med 2011, 3:97ra80.
3. Gaspar H.B., Cooray S., Gilmour K.C., Parsley K.L., Adams S., Howe S.J., et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 2011, 3:97ra79.
4. Lamb L.S., Bowersock J., Dasgupta A., Gillespie G.Y., Su Y., Johnson A., et al. Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy. PLoS One 2013, 8(1):e51805.
5. Chen F., Cai B., Gao Y., Yuan X., Cheng F., Wang T., et al. Suicide gene-mediated ablation of tumor-initiating mouse pluripotent stem cells. Biomaterials 2013, 34(6):1701-1711.
6. Finkelshtein D., Werman A., Novick D., Barak S., Rubinstein M. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci U S A 2013, 110(18):7306-7311.
7. Burns J.C., Friedmann T., Driever W., Burrascano M., Yee J.K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A 1993, 90:8033-8037.
8. Li Y., Drone C., Sat E., Ghosh H.P. Mutational analysis of the vesicular stomatitis virus glycoprotein G for membrane fusion domains. JVirol 1993, 67:4070-4077.
9. Strappe P.M., Hampton D.W., Cachon-Gonzalez B., Fawcett J.W., Lever A. Delivery of a lentiviral vector in a pluronic F127 gel to cells of the central nervous system. Eur J Pharm Biopharm 2005, 61:126-133.
10. Waehler R., Russell S.J., Curiel D.T. Engineering targeted viral vectors for gene therapy. Nat Rev Genet 2007, 8:573-587.
11. Guibinga G.H., Hall F.L., Gordon E.M., Ruoslahti E., Friedmann T. Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype. Mol Ther 2004, 9(1):76-84.
12. Kameyama Y., Kawabe Y., Ito A., Kamihira M. Antibody-dependent gene transduction using gammaretroviral and lentiviral vectors pseudotyped with chimeric vesicular stomatitis virus glycoprotein. JVirol Methods 2008, 153(1):49-54.
13. Padmashali R.M., Andreadis S.T. Engineering fibrinogen-binding VSV-G envelope for spatially- and cell-controlled lentivirus delivery through fibrin hydrogels. Biomaterials 2011, 32(12):3330-3339.
14. Dreja H., Piechaczyk M. The effects of N-terminal insertion into VSV-G of an scFv peptide. Virol J 2006, 3:69.
15. Guinivan P., Ladda R.L. Decrease in epidermal growth factor receptor levels and production of material enhancing epidermal growth factor binding accompany the temperature-dependent changes from normal to transformed phenotype. Proc Natl Acad Sci U S A 1979, 76(7):3377-3381.
16. Yewale C., Baradia D., Vhora I., Patil S., Misra A. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials 2013, 34(34):8690-8707.
17. Udayachander M., Meenakshi A., Ansamma J., Muthiah R. Lymphoma-associated antigen (LAA): isolation, characterization and clinical evaluation. Br J Cancer 1983, 48(5):717-725.
18. Deutsch Y.E., Tadmor T., Podack E.R., Rosenblatt J.D. CD30: an important new target in hematologic malignancies. Leuk Lymphoma 2011, 52(9):1641-1654.
19. Matthey B., Borchmann P., Schnell R., Tawadros S., Lange H., Huhn M., et al. Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas invivo. Int J Cancer 2004, 111:568-574.
20. Braschoss S., Hirsch B., Duebel S., Stein H., Duerkop H. New anti-CD30 human pancreatic ribonuclease-based immunotoxin reveals strong and specific cytotoxicity invivo. Leuk Lymphoma 2007, 48:1179-1186.
21. Pardo A., Stoecker M., Kampmeier F., Melmer G., Fischer R., Thepen T., et al. Invivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model. Cancer Immunol Immunother 2012, 61:1617-1626.
22. Ingrao D., Majdoul S., Seye A.K., Galy A., Fenard D. Concurrent measures of fusion and transduction efficiency of primary CD34+ cells with human immunodeficiency virus 1-based lentiviral vectors reveal different effects of transduction enhancers. Hum Gene Ther Methods 2014, 25(1):48-56.
23. Höfig I., Atkinson M.J., Mall S., Krackhardt A.M., Thirion C., Anastasov N. Poloxamer synperonic F108 improves cellular transduction with lentiviral vectors. JGene Med 2012, 14:549-560.
24. Anastasov N., Bonzheim I., Rudelius M., Klier M., Dau T., Angermeier D., et al. C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway. Haematologica 2010, 95(5):760-767.
25. Funke S., Maisner A., Muehlebach M.D., Koehl U., Grez M., Cattaneo R., et al. Targeted cell entry of lentiviral vectors. Mol Ther 2008, 16:1427-1436.
26. Cornetta K., Anderson W.F. Protamine sulfate as an effective alternative to polybrene in retroviral-mediated gene-transfer: implications for human gene therapy. JVirol Methods 1989, 23:187-194.
27. Toyoshima K., Vogt P.K. Enhancement and inhibition of avian sarcoma viruses by polycations and polyanions. Virology 1969, 38:414-426.
28. Davis H.E., Rosinski M., Morgan J.R., Yarmush M.L. Charged polymers modulate retrovirus transduction via membrane charge neutralization and virus aggregation. Biophys J 2004, 86:1234-1242.
29. Hanenberg H., Xiao X.L., Dilloo D., Hashino K., Kato I., Williams D.A. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med 1996, 2:876-882.
30. Sandrin V., Boson B., Salmon P., Gay W., Nègre D., Le Grand R., et al. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 2002, 100:823-832.
31. Haas D.L., Case S.S., Crooks G.M., Kohn D.B. Critical factors influencing stable transduction of human CD34(+) cells with HIV-1-derived lentiviral vectors. Mol Ther 2000, 2:71-80.
32. Fenard D., Ingrao D., Seye A., Buisset J., Genries S., Martin S., et al. Vectofusin-1, a new viral entry enhancer, strongly promotes lentiviral transduction of human hematopoietic stem cells. Mol Ther Nucleic Acids 2013, 2:e90.
33. Wu D.T., Seita Y., Zhang X., Lu C.W., Roth M.J. Antibody-directed lentiviral gene transduction for live-cell monitoring and selection of human iPS and hES cells. PLoS One 2012, 7:e34778.
34. Zhang K.X., Moussavi M., Kim C., Chow E., Chen I.S., Fazli L., et al. Lentiviruses with trastuzumab bound to their envelopes can target and kill prostate cancer cells. Cancer Gene Ther 2009, 16:820-831.
35. Morizono K., Xie Y., Ringpis G.E., Johnson M., Nassanian H., Lee B., et al. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med 2005, 11:346-352.
36. Ayala-Breton C., Barber G.N., Russell S.J., Peng K.W. Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. Hum Gene Ther 2012, 23:484-491.
37. Farley D.C., Iqball S., Smith J.C., Miskin J.E., Kingsman S.M., Mitrophanous K.A. Factors that influence VSV-G pseudotyping and transduction efficiency of lentiviral vectors - invitro and invivo implications. JGene Med 2007, 9:345-356.
38. Schlehuber L.D., Rose J.K. Prediction and identification of a permissive epitope insertion site in the vesicular stomatitis virus glycoprotein. JVirol 2004, 78(10):5079-5087.
39. Yu J.H., Schaffer D.V. Selection of novel vesicular stomatitis virus glycoprotein variants from a peptide insertion library for enhanced purification of retroviral and lentiviral vectors. JVirol 2006, 80:3285-3292.
40. Kaikkonen M.U., Lesch H.P., Pikkarainen J., Raety J.K., Vuorio T., Huhtala T., et al. (Strept)avidin-displaying lentiviruses as versatile tools for targeting and dual imaging of gene delivery. Gene Ther 2009, 16:894-904.
41. Jeong Lee H., Pardridge W.M. Drug targeting to the brain using avidin-biotin technology in the mouse. JDrug Target 2000, 8:413-424.
42. Roche S., Albertini A.A., Lepault J., Bressanelli S., Gaudin Y. Structures of vesicular stomatitis virus glycoprotein: membrane fusion revisited. Cell Mol Life Sci 2008, 65:1716-1728.
43. Albertini A.A., Mérigoux C., Libersou S., Madiona K., Bressanelli S., Roche S., et al. Characterization of monomeric intermediates during VSV glycoprotein structural transition. PLoS Pathog 2012, 8(2):e1002556.